dacomitinib + antacid

This is a combination of dacomitinib, an oral irreversible small molecule inhibitor of the human epidermal growth factor receptor (EGFR) family (including EGFR/HER1, HER2, and HER4) tyrosine kinases, and an antacid. Dacomitinib is primarily indicated as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. The addition of an antacid may be considered in clinical practice to manage gastrointestinal symptoms or acid-related side effects; however, coadministration can affect drug absorption due to pH-dependent solubility. Clinical data show that short-acting antacids do not significantly alter dacomitinib exposure if administered at least 6 hours before or 10 hours after the kinase inhibitor[2][3][6]. This combination should not be confused with fixed-dose combinations; it refers to concurrent use.